Violet-Toothed Polypore

Metadata

Regulatory Status

United States

• Not marketed as a dietary supplement
• No FDA GRAS status
• Not assessed by NIH for clinical investigation
• Widely distributed in North American temperate forests on dead hardwoods, especially birch, beech, and oak
• Research conducted at institutions including Messiah College (Pennsylvania) and other US universities

European Union

• Not assessed under EU Novel Food Regulation (EU) 2015/2283
• No EMA/HMPC monograph
• Recognized in European mycological surveys as a common saprotrophic polypore
• Some antibacterial research conducted in Algeria on specimens from North African populations

East Asia

• Not listed in the Chinese Pharmacopoeia or Japanese Pharmacopoeia
• No traditional use documented in TCM, Kampo, or Korean traditional medicine
• Significant recent research from South Korean groups on polysaccharide immunomodulation and genome decoding
• Distributed throughout temperate regions of Asia

General

• The species is classified as non-toxic and has been described as edible by some mycological sources, though it is not consumed as food due to its tough texture
• No regulatory approval as a medicinal product in any jurisdiction

Conditions & Indications

Primary (Preclinical Evidence)

• Cancer immune support (in vitro) — Trichaptum biforme polysaccharides (TBP) stimulate the innate immune system by enhancing macrophage secretion of pro-inflammatory cytokines IL-1-beta and TNF-alpha from THP-1 cells at concentrations of 10 and 320 micrograms/mL (p < 0.01). NK cell-mediated antitumor activity was significantly enhanced when NK cells were treated with TBP (320 micrograms/mL) plus IL-2 (100 units/mL), with increased cytotoxic activity and IFN-gamma secretion compared to controls (p < 0.01). These findings suggest TBP holds promise as a candidate for bolstering anticancer immune responses (Lee et al. 2024, Int J Biol Macromol).
• Bacterial infections (in vitro) — Extracts of T. biforme demonstrated strong antibacterial effects against Gram-positive bacteria (Staphylococcus aureus, Bacillus subtilis, Streptococcus) and activity against the Gram-negative Escherichia coli. GC-MS analysis identified 30 components in the active extract, with caryophyllene oxide, octodrine, and phenolic compounds identified as likely antimicrobial agents (Yakhlef et al. 2020; Chikwem et al. 2020).

Secondary (Preclinical Evidence)

• Antitumor activity (in vitro, indirect evidence) — Ergosterol peroxide isolated from T. biforme fruiting bodies is a well-characterized anticancer compound across the Basidiomycota, with documented activity against multiple cancer cell lines through apoptosis induction, NF-kB inhibition, and immunomodulation. 9(11)-Dehydroergosterol peroxide, first identified in T. biforme, may have analogous anticancer properties (Lee et al. 2024).
• Antioxidant activity — The phenolic compound content of T. biforme extracts contributes to free radical scavenging capacity, though this has been less thoroughly characterized than the antimicrobial and immunomodulatory activities.
• Antifungal activity — Extracts demonstrated antifungal activity alongside antibacterial effects, expanding the antimicrobial spectrum to include fungal pathogens (Chikwem et al. 2020).

Emerging/Preclinical

• Polysaccharide-based cancer immunotherapy — The potent macrophage activation and NK cell enhancement by TBP suggests potential development as a biological response modifier for cancer adjunctive therapy, analogous to PSK from Turkey Tail, though at a much earlier stage of investigation
• Genome-informed drug discovery — The recent decoding of the T. biforme genome (proposed reclassification to Pallidohirschioporus biformis) has provided insights into carbohydrate degradation and polysaccharide synthesis pathways, enabling targeted investigation of specific biosynthetic gene clusters for bioactive polysaccharide production (Kim et al. 2025, Gene)
• Bioremediation applications — T. biforme demonstrates methylene blue decolorization and gum degradation activities, reflecting enzymatic capabilities that may also indicate production of oxidative enzymes with potential medicinal applications

Mechanism of Action

Primary Mechanisms

1. Polysaccharide-mediated macrophage activation and cytokine induction: TBP (total polysaccharide content 78.18%) activates macrophages derived from THP-1 monocytes, resulting in significantly increased secretion of IL-1-beta and TNF-alpha at concentrations of 10 and 320 micrograms/mL. The mechanism likely involves recognition of beta-glucan structures by macrophage pattern recognition receptors, primarily Dectin-1 (CLEC7A) and Toll-like receptor 2/4 (TLR2/4). Receptor engagement triggers NF-kB and MAPK signaling cascades, leading to transcriptional activation of pro-inflammatory cytokine genes. TNF-alpha has direct tumor cell killing activity and promotes adaptive antitumor immunity, while IL-1-beta activates the inflammasome pathway and enhances T-cell priming.

2. Polysaccharide-mediated NK cell activation and IFN-gamma production: TBP at 320 micrograms/mL, in combination with IL-2 (100 units/mL), significantly enhanced NK cell cytotoxic activity against target cells and increased IFN-gamma secretion. NK cells are critical effectors of innate antitumor immunity, and their activation by polysaccharides represents a key mechanism for the immunomodulatory anticancer effects observed across medicinal mushroom polysaccharides. The synergy with IL-2 suggests that TBP may lower the activation threshold for NK cell effector functions, potentially amplifying the effects of endogenous IL-2 in vivo.

3. Caryophyllene oxide and octodrine-mediated antibacterial activity: GC-MS analysis of the antibacterial extract identified 30 compounds, with caryophyllene oxide (a sesquiterpene epoxide), octodrine (2-amino-6-methylheptane, a sympathomimetic amine), phenolic compounds, and fatty acid esters as primary contributors to antimicrobial activity. Caryophyllene oxide disrupts bacterial cell membrane integrity through insertion into the lipid bilayer, while phenolic compounds inhibit microbial enzyme systems and cross-link with bacterial surface proteins. The preferential activity against Gram-positive bacteria is consistent with direct membrane access unimpeded by the outer membrane present in Gram-negative organisms.

Secondary Mechanisms

4. Ergosterol peroxide-mediated cytotoxicity and immunomodulation: Ergosterol peroxide (5alpha,8alpha-epidioxyergosta-6,22-dien-3beta-ol) is a well-characterized bioactive sterol found across the Basidiomycota. Its anticancer mechanisms include induction of apoptosis through mitochondrial pathways (cytochrome c release, caspase activation), inhibition of NF-kB signaling (suppressing anti-apoptotic gene expression), and immunosuppressive effects through inhibition of T-lymphocyte mitogen-induced proliferation. The presence of both immunostimulatory polysaccharides and immunosuppressive ergosterol peroxide in T. biforme creates a complex immunomodulatory profile that may depend on the extraction method and fraction used.

5. Beta-glucan prebiotic effects: The high polysaccharide content (78.18%) of T. biforme suggests significant prebiotic potential. Beta-glucans resist upper gastrointestinal digestion and reach the colon intact, where they serve as substrates for beneficial gut bacteria. Colonic fermentation of these polysaccharides produces short-chain fatty acids (SCFAs) including butyrate, which supports gut barrier integrity, has local anti-inflammatory effects, and may have systemic immunomodulatory effects.

6. Phenolic compound-mediated antioxidant activity: The phenolic compounds identified in T. biforme extracts contribute to antioxidant activity through free radical scavenging (hydrogen atom transfer and single electron transfer mechanisms) and metal chelation. These compounds may also contribute to the antibacterial activity through disruption of bacterial redox homeostasis.

Clinical Evidence Summary

No human clinical trials have been conducted with Trichaptum biforme. The evidence base consists of in vitro studies of immunomodulatory, antibacterial, and chemical characterization, supplemented by a recent genome study.

Key Preclinical Studies

Evidence Limitations

• The primary immunomodulatory study (Lee et al. 2024) is a single publication, albeit in a reputable journal (International Journal of Biological Macromolecules); independent replication is needed
• All evidence is in vitro; no animal models of cancer or infection have been used to test T. biforme preparations
• The antibacterial studies used crude extracts without isolating individual active compounds to determine minimum inhibitory concentrations
• No pharmacokinetic data exists for any T. biforme bioactive compound
• The polysaccharide fraction (TBP) has not been structurally characterized in detail (monosaccharide composition, glycosidic linkages, molecular weight distribution); the study primarily assessed total polysaccharide content and biological activity
• The dual immunostimulatory (polysaccharides) and immunosuppressive (ergosterol peroxide) properties create complexity in predicting net immunological effects of whole extracts
• No standardized extract or preparation exists
• Taxonomic revision (to Pallidohirschioporus biformis) may cause confusion in the literature

Safety Profile

General Assessment

Trichaptum biforme is not known to be toxic. Some mycological sources describe it as edible, though it is not consumed as food due to its tough, leathery texture. The species is extremely common in temperate forests worldwide and has no reports of adverse effects in the mycological or toxicological literature. The absence of clinical trials means that formal safety evaluation in humans has not been conducted.

Contraindications

• Known allergy to mushrooms (Basidiomycota): Standard precaution for all medicinal mushroom preparations
• Active autoimmune disease: The polysaccharide fraction stimulates potent macrophage activation and pro-inflammatory cytokine secretion (TNF-alpha, IL-1-beta); immune stimulation could theoretically exacerbate autoimmune conditions
• Organ transplant recipients: Immunostimulatory polysaccharides may counteract immunosuppressive therapy required to prevent graft rejection
• Pregnancy and lactation: No reproductive safety data available; avoid until safety is established

Drug Interactions

• No documented drug interactions in humans
• Theoretical interaction with immunosuppressant medications (cyclosporine, tacrolimus, corticosteroids) due to potent immunostimulatory effects of TBP
• Theoretical interaction with checkpoint inhibitor immunotherapy (nivolumab, pembrolizumab) — additive immune stimulation
• Octodrine (2-amino-6-methylheptane), identified in the extract, is a sympathomimetic amine; if present in bioavailable quantities, it could theoretically interact with cardiovascular medications, MAO inhibitors, or stimulant drugs, though the concentration in mushroom extracts is likely too low for systemic effects

Side Effects

• No side effects documented in the literature due to absence of human clinical use
• The presence of the sympathomimetic amine octodrine warrants awareness, though its concentration in fruiting body extracts and oral bioavailability are unknown

Toxicology

• No formal toxicology studies published
• The common occurrence and widespread distribution of T. biforme without reports of environmental or incidental toxicity provides indirect evidence of low toxicity
• Ergosterol peroxide is cytotoxic to cancer cells but shows selectivity over normal cells in studies of related species

Clinical Dosage

No clinically validated dosage exists for Trichaptum biforme due to the complete absence of human trials.

Experimental Dosages (Preclinical Research)

• Polysaccharide immunomodulation (in vitro): Significant macrophage activation at 10 and 320 micrograms/mL; NK cell enhancement at 320 micrograms/mL (with IL-2 co-stimulation)
• Antibacterial activity (in vitro): Crude extract inhibition zones measured in disc diffusion assays; minimum inhibitory concentrations not formally determined in most studies
• Polysaccharide content: Total polysaccharide content of the extract was 78.18%, providing guidance for potential extract standardization

Traditional Preparation

• No traditional medicinal preparation is documented for T. biforme in any pharmacopoeia or ethnobotanical record
• Like other tough polypores, theoretical preparation would involve extended decoction (2-4 hours simmering) to extract water-soluble polysaccharides
• The n-hexane fraction (which yielded the steroidal compounds) would not be extracted by aqueous preparation methods

Product Quality Considerations

• No commercial supplements of Trichaptum biforme are available
• The high polysaccharide content (78.18%) of the studied extract suggests that T. biforme could be a particularly rich source of immunomodulatory polysaccharides if developed commercially
• The presence of both immunostimulatory polysaccharides and cytotoxic ergosterol derivatives in different fractions suggests that extraction method would critically determine the bioactivity profile of any product
• The recently decoded genome provides a foundation for understanding polysaccharide biosynthesis pathways and potentially optimizing production through strain selection or culture condition manipulation

Sources

• Lee HW, Park E, Lee S, et al. Phytochemical analysis and immune-modulatory potential of Trichaptum biforme polysaccharides: implications for cancer. Int J Biol Macromol. 2024;283:137452
• Yakhlef D, Dib S, Fortas Z. Antibacterial activity and GC-MS analysis of Trichaptum biforme extract. J Mycol Med. 2020;30(3):100932
• Chikwem JO, Okafor TS, Nwankiti O, et al. Antimicrobial potential of Trichaptum biforme and Bjerkandera adusta from Pennsylvania, USA. J Nat Sci Res. 2020;11(10):1-6
• Kim YR, Lee JY, Park SH, et al. Trichaptum biforme (Pallidohirschioporus biformis) genome decoding provides insights into carbohydrate degradation and polysaccharide synthesis. Gene. 2025;933:149030
• Krupodorova TA, Barshteyn VYu, Kizitska TO. Antiproliferative activity and cytotoxicity of some medicinal wood-destroying mushrooms from Russia. Int J Med Mushrooms. 2018;20(3):301-310
• Ryvarden L, Gilbertson RL. European Polypores. Part 2. Synopsis Fungorum 7. Oslo: Fungiflora; 1994
• Moncalvo JM, Ryvarden L. A nomenclatural study of the Coriolaceae sensu lato. Synopsis Fungorum 11. Oslo: Fungiflora; 1997
• Wasser SP. Medicinal mushroom science: current perspectives, advances, evidences, and challenges. Biomed J. 2014;37(6):345-356

Connections

• The polysaccharide-based immunomodulatory mechanism (macrophage TNF-alpha/IL-1-beta induction, NK cell IFN-gamma enhancement) closely parallels the activity of PSK and PSP from Turkey Tail (Trametes versicolor), the gold standard for medicinal mushroom immunotherapy; TBP could represent a novel source of analogous biological response modifiers
• The NK cell activation profile of TBP is reminiscent of the well-documented NK cell enhancement by lentinan from Shiitake and D-fraction from Maitake, suggesting shared beta-glucan receptor-mediated immune activation pathways
• The presence of ergosterol peroxide as a secondary metabolite is shared with many other Polyporaceae species including Fomes fomentarius and Fomitopsis betulina; this compound class provides cytotoxic activity complementary to the immunostimulatory polysaccharides
• Compare with Schizophyllum commune, another polysaccharide-rich medicinal polypore with extensively characterized immunomodulatory beta-glucans (schizophyllan); T. biforme’s higher total polysaccharide content (78.18%) may suggest an even richer polysaccharide source
• The antibacterial compound profile (caryophyllene oxide, octodrine) differs from the laccase-mediated cinnabarinic acid pathway of Pycnoporus cinnabarinus, representing an alternative antimicrobial strategy within the Polyporaceae
• The recent genome decoding of T. biforme opens the door to genomics-guided discovery of bioactive polysaccharide biosynthetic pathways, a cutting-edge approach that could accelerate the development of this and related species as sources of standardized medicinal preparations
• Despite morphological similarity to polypore fungi, T. biforme is taxonomically placed in the order Hymenochaetales rather than Polyporales, making it phylogenetically distinct from most other species in the Polyporaceae family referenced in this knowledge base